June 2023 – ITHEMYC kicks off
Novel Immunotherapies for Tuberculosis and other Mycobacterial Diseases (ITHEMYC)
The Horizon Europe programme has funded the ITHEMYC project to establish a critical path for selection of promising innovative adjunct TB immunotherapies and progress 2 of these immunotherapies to completion of preclinical proof of concept.